Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT03675737 |
Title | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | No |
Sponsors | Merck Sharp & Dohme Corp. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | AUS |